Skip to Main text
The Nitto Group strives to become a centennial company that is always trusted by customers, embraced by employees with pride, makes an active contribution to society, and continuously grows on a global scale.
|2017/Jan/11||Nitto Named One of the 2016 Top 100 Global IP/Patents-related Innovators, Marking its Sixth Consecutive Year on the List|
|2016/Nov/11||Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH|
|2016/Nov/02||Initiation of Phase I Clinical Trial for Seasonal Influenza HA Vaccine Sublingual Tablet|
Back to Page Top